PSTX - Poseida Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference

PR Newswire

SAN DIEGO , Sept. 7, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that the Company's Chief Financial Officer, Johanna Mylet , will present virtually at the H.C. Wainwright 24th Annual Global Investment Conference being held in New York, NY from September 12-14, 2022 . The on-demand session will become available at 7:00am ET on September 12, 2022 .

A webcast of the presentation will be available on the Investors & Media Section of Poseida's website, www.poseida.com . A replay of the webcast will be available for 30 days following the presentation.

About Poseida Therapeutics, Inc.
Poseida Therapeutics is a clinical-stage biopharmaceutical company dedicated to utilizing our proprietary genetic engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure. We have discovered and are developing a broad portfolio of product candidates in a variety of indications based on our core proprietary platforms, including our non-viral piggyBac® DNA Delivery System, Cas-CLOVER™ Site-specific Gene Editing System and nanoparticle- and AAV-based gene delivery technologies. Our core platform technologies have utility, either alone or in combination, across many cell and gene therapeutic modalities and enable us to engineer our portfolio of product candidates that are designed to overcome the primary limitations of current generation cell and gene therapeutics. To learn more, visit www.poseida.com and connect with us on Twitter and LinkedIn .

Investor contact:
Alex Lobo
Stern Investor Relations
Alex.lobo@sternir.com

Media contact:
Sarah Thailing
Senior Director, Corporate Communications and IR
Poseida Therapeutics, Inc.
858-605-3717
sthailing@poseida.com

SOURCE Poseida Therapeutics, Inc.